| Category | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Neurofibromatosis
|
NHLBI
|
5R01HL062974-09
|
|
Neurofibromin, Neural Crest and Cardiac Development
|
EPSTEIN, JONATHAN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$338,145
|
|
Neurofibromatosis
|
NHLBI
|
5K08HL075179-04
|
|
Neurofibromin, Ras & NFAT in Cardiovascular Development
|
ISMAT, FRAZ
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$133,920
|
|
Neurofibromatosis
|
NINDS
|
5R01NS034783-13
|
|
Function of Merlin, a Drosophila NF2 gene homologue
|
FEHON, RICHARD
|
UNIVERSITY OF CHICAGO
|
IL
|
$300,799
|
|
Neurofibromatosis
|
NINDS
|
5R01NS028840-18
|
|
Mitogenic Activities in Neurofibromatosis
|
RATNER, NANCY
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$324,008
|
|
Neurofibromatosis
|
NCI
|
5R01CA106416-03
|
|
Using Zebrafish to Identify and Analyze Cancer Genes
|
LEES, JACQUELINE
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$398,901
|
|
Neurofibromatosis
|
NCI
|
1R15CA132006-01
|
|
Regulation of Mixed Lineage Kinase 3 by the tumor suppressor protein Merlin
|
CHADEE, DEBORAH
|
UNIVERSITY OF TOLEDO
|
OH
|
$216,000
|
|
Neurofibromatosis
|
NCI
|
1R01CA127008-01A1
|
|
REGULATION AND ROLE OF MTOR IN NEUROFIBROMIN GROWTH CONTROL
|
WEBER, JASON
|
WASHINGTON UNIVERSITY
|
MO
|
$341,561
|
|
Neurofibromatosis
|
NCI
|
1R01CA122804-01A2
|
|
Novel Treatment of NF-1 Associated Malignant Peripheral Nerve Sheath Tumors
|
CARROLL, STEVEN
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$300,875
|
|
Neurofibromatosis
|
NIDCD
|
5R01DC005985-04
|
|
Phenotypic Determinants of Vestibular Schwannomas
|
WELLING, D
|
OHIO STATE UNIVERSITY
|
OH
|
$301,597
|
|
Neurofibromatosis
|
NCI
|
5R01CA117872-03
|
|
The Role of Merlin Phosphorylation on its Tumor Suppressive Activity
|
YE, KEQIANG
|
EMORY UNIVERSITY
|
GA
|
$207,330
|
|
Neurofibromatosis
|
NCI
|
1F32CA128335-01A1
|
|
Merlin regulation of glial cell growth and motility
|
HOUSHMANDI, SHERVIN
|
WASHINGTON UNIVERSITY
|
MO
|
$49,646
|
|
Neurofibromatosis
|
NINDS
|
5R01NS050509-03
|
|
Spinal abnormalities in neurofibomatosis type 1
|
VISKOCHIL, DAVID
|
UNIVERSITY OF UTAH
|
UT
|
$277,477
|
|
Neurofibromatosis
|
NINDS
|
5K23NS052500-04
|
|
Osseous Abnormalities in Neurofibromatosis Type 1
|
STEVENSON, DAVID
|
UNIVERSITY OF UTAH
|
UT
|
$176,094
|
|
Neurofibromatosis
|
NCI
|
5R01CA112399-04
|
|
MLK3 function in neurofibromatosis tumor cells
|
KYRIAKIS, JOHN
|
TUFTS MEDICAL CENTER
|
MA
|
$244,195
|
|
Neurofibromatosis
|
NCI
|
5R01CA078524-09
|
|
Structure, Function and Regulation of Merlin
|
IP, WALLACE
|
UNIVERSITY OF CINCINNATI
|
OH
|
$262,736
|
|
Neurofibromatosis
|
NINDS
|
5R01NS055339-03
|
|
Cell Signaling and Dendritic Spine Plasticity
|
WU, GANG-YI
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$254,888
|
|
Neurofibromatosis
|
NINDS
|
5R01NS048353-05
|
|
Role of Neuregulin-1 in Schwann Cell Neoplasia
|
CARROLL, STEVEN
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$254,350
|
|
Neurofibromatosis
|
NINDS
|
5R01NS053900-03
|
|
Cellular and molecular basis of malignant astrocytoma
|
ZHU, YUAN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$309,361
|
|
Neurofibromatosis
|
NCI
|
5R01CA129814-02
|
|
Elucidating the role of the mTOR pathway in NF1-related tumorigenesis
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$300,291
|
|
Neurofibromatosis
|
NINDS
|
2P01NS024279-20A2
|
0014
|
Molecular Genetics Of Meningioma and Neurofibromatosis Related Disorders
|
GUSELLA, JAMES
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$379,828
|
|
Neurofibromatosis
|
NINDS
|
2P01NS024279-20A2
|
0016
|
Vector Query and Therapy For TSC and NF2 Lesions
|
BREAKEFIELD, XANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$291,359
|
|
Neurofibromatosis
|
NINDS
|
2P01NS024279-20A2
|
9009
|
CLINICAL CORE
|
THIELE, ELIZABETH
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$164,880
|
|
Neurofibromatosis
|
NINDS
|
2P01NS024279-20A2
|
9010
|
NEUROPATHOLOGY CORE
|
STEMMER-RACHAMIMOV, ANAT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$189,907
|
|
Neurofibromatosis
|
NINDS
|
5R44NS053110-03
|
|
Advanced Molecular Diagnostic Test for Neurofibromatosis
|
LIM, MARK
|
AMBERGEN, INC
|
MA
|
$383,348
|
|
Neurofibromatosis
|
NCI
|
5R01CA107201-04
|
|
Connecting PTEN and NF2 cancer predisposition syndromes
|
GEORGESCU, MARIA-MAGDALENA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$254,494
|
|
Neurofibromatosis
|
NIDCD
|
5K08DC008523-02
|
|
ErbB receptor regulation of Vestibular Schwannomas
|
DOHERTY, JONI
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$186,678
|
|
Neurofibromatosis
|
NCI
|
2R01CA074177-11A1
|
|
Neurofibromatosis type 1 Gene Regulates Myelopoiesis
|
CLAPP, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$338,107
|
|
Neurofibromatosis
|
NCI
|
5R01CA113733-04
|
|
Molecular Function of the Nf2 Tumor Suppressor, Merlin
|
MCCLATCHEY, ANDREA
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$272,786
|
|
Neurofibromatosis
|
NCI
|
5F32CA124030-03
|
|
Stem Cell Regulation by the NF2 Tumor Suppressor Merlin
|
GLADDEN, ANDREW
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$48,796
|
|
Neurofibromatosis
|
NCI
|
5F32CA123752-03
|
|
Elucidation of NF2's tumor supressive function
|
YI, CHUNLING
|
WISTAR INSTITUTE
|
PA
|
$50,428
|
|
Neurofibromatosis
|
NINDS
|
5R01NS049096-03
|
|
Neurobiology and Treatment of Reading Disability in NF1
|
CUTTING, LAURIE
|
HUGO W. MOSER RES INST KENNEDY KRIEGER
|
MD
|
$391,734
|
|
Neurofibromatosis
|
NCI
|
5R01CA118032-02
|
|
Schwann Cells in Neurofibromatosis Type 2 (NF2)
|
RATNER, NANCY
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$285,000
|
|
Neurofibromatosis
|
NINDS
|
5F30NS060322-02
|
|
The role of Pak1 in regulating plexiform neurofibroma formation
|
MCDANIEL, ANDREW
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$35,084
|
|
Neurofibromatosis
|
NIMH
|
8R01MH084315-09
|
|
Mechanisms for Neurological Dysfunction in NF1
|
SILVA, ALCINO
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$445,191
|
|
Neurofibromatosis
|
NINDS
|
1F30NS063626-01
|
|
Regulation of Ras isoforms in malignant peripheral nerve sheath tumors
|
BROSSIER, NICOLE
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$30,725
|
|
Neurofibromatosis
|
NINDS
|
1P50NS057531-01A2
|
0001
|
Bench to Bedside: Signaling
|
THOMAS, GEORGE
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$741,181
|
|
Neurofibromatosis
|
NINDS
|
1P50NS057531-01A2
|
0002
|
Ras Proteins in NF1
|
RATNER, NANCY
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$168,335
|
|
Neurofibromatosis
|
NINDS
|
1P50NS057531-01A2
|
9002
|
Xenograft Core for NF1 Experimental Therapeutics
|
CRIPE, TIMOTHY
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$92,327
|
|
Neurofibromatosis
|
NINDS
|
1P50NS057531-01A2
|
9003
|
Pathology Core for NF1 Research
|
RIZVI, TILAT
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$61,310
|
|
Neurofibromatosis
|
NIGMS
|
1R01GM084220-01A1
|
|
Understanding Mechanisms Underlying Drosophila Neurofibromatosis-1 Defects
|
BERNARDS, ANDRE
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$351,833
|
|
Neurofibromatosis
|
NINDS
|
5P50NS052606-04
|
0001
|
NF Center: From Animal Models to Therapeutics
|
PARADA, LUIS
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$212,903
|
|
Neurofibromatosis
|
NINDS
|
5P50NS052606-04
|
0002
|
NF Center: From Animal Models to Therapeutics
|
CLAPP, DAVID
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$212,903
|
|
Neurofibromatosis
|
NINDS
|
5P50NS052606-04
|
0003
|
NF Center: From Animal Models to Therapeutics
|
INGRAM, DAVID
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$212,903
|
|
Neurofibromatosis
|
NIAMS
|
5P30AR050948-05
|
0009
|
Natural History of Dermal Neurofibromas In Patients with Neurofibromatosis 1
|
ELMETS, CRAIG
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$45,218
|
|
Neurofibromatosis
|
NINDS
|
1U01NS055849-01A2
|
0001
|
Preclinical Testing of Targeted Therapies for Neurofibromas
|
CLAPP, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$619,877
|
|
Neurofibromatosis
|
NCRR
|
5P51RR000163-49
|
6156
|
ROLE OF HYALURONAN IN SCHWANNOMA GROWTH
|
SHERMAN, LARRY
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$54,119
|
|
Neurofibromatosis
|
NIA
|
5P51RR000163-49
|
6156
|
ROLE OF HYALURONAN IN SCHWANNOMA GROWTH
|
SHERMAN, LARRY
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$1,393
|
|
Neurofibromatosis
|
NCRR
|
5M01RR020359-04
|
7308
|
EARLY IDENTIFICATION OF COGNITIVE DEFICITS IN CHILDREN WITH NEUROFIBROMATOSIS TP
|
ACOSTA, MARIA
|
CHILDREN'S RESEARCH INSTITUTE
|
DC
|
$19,167
|
|
Neurofibromatosis
|
NCRR
|
5M01RR000188-44
|
7780
|
CLINICAL TRIAL: PHASE II TRIAL OF PIRFENIDONE IN CHILDREN, ADOLESCENTS, AND YOUN
|
BLANEY, SUSAN
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$2,231
|
|
Neurofibromatosis
|
NCRR
|
5M01RR008084-15
|
7937
|
SPINAL ABNORMALITIES IN NEUROFIBROMATOSIS
|
SCHORRY, ELIZABETH
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$6,762
|
|
Neurofibromatosis
|
NCRR
|
5M01RR000064-44
|
8612
|
NEUROFIBROMATOSIS SCREENING
|
STEVENSON, DAVID
|
UNIVERSITY OF UTAH
|
UT
|
$4,126
|
|
Neurofibromatosis
|
NCI
|
1Z01BC010539-06
|
|
Identification of Modifier Gene of Tumors Associated with NF1 and Astrocytoma
|
REILLY, KARLYNE
|
NIH
|
|
$698,325
|
|
Neurofibromatosis
|
NCI
|
1Z01BC010734-03
|
|
Cutaneous Lesions in Neurofibromatosis Type I and Other Pre-cancerous Syndromes
|
HORNYAK, THOMAS
|
NIH
|
|
$50,081
|
|
Neurofibromatosis
|
NCI
|
1Z01BC010801-02
|
|
Development of Therapies for Neurofibromatosis Type 1 Related Tumors and other G
|
WIDEMANN, BRIGITTE
|
NIH
|
|
$569,726
|
|
Neurofibromatosis
|
NHGRI
|
1Z01HG200329-04
|
|
Variation in Gene Expression in Neurofibromatosis Type 1
|
BIESECKER, LESLIE
|
NIH
|
|
$225,590
|
|
Neurofibromatosis
|
NINDS
|
1Z01NS003053-01
|
|
Neuro-oncology of Familial Neoplasia Syndromes
|
LONSER, RUSSELL
|
NIH
|
|
$1,034,055
|
|
Neurofibromatosis
|
NCI
|
1Z01SC009431-14
|
|
Histologic and Molecular Characterization of Solid Pediatric Tumors
|
TSOKOS, MARIA
|
NIH
|
|
$316,500
|
